- This topic is empty.
-
Posts
-
For organizations evaluating a cost-conscious partner to move biologic candidates from early concept into preclinical and IND-enabling studies, Yaohai Bio-Pharma presents a model built specifically around microbial expression systems rather than generic mammalian platforms. Founded in 2010, Yaohai Bio-Pharmaceutical operates as a Microbial CRDMO (Contract Research, Development, and Manufacturing Organization), offering a one-stop pathway from R&D and process development through GMP manufacturing for customers across the USA, China, Europe (EU), and Australia.
Addressing the Core Pain Points of Preclinical Development
Preclinical teams frequently encounter low yields and stability issues in mammalian expression systems, along with severe aggregation in scFv/Fab fragments, high biopharmaceutical manufacturing costs, and complex regulatory hurdles when preparing for multi-region submissions. Yaohai Bio-Pharma’s strategic positioning directly targets these constraints by specializing in microbial expression systems, which the company states can reduce manufacturing overhead compared with mammalian systems while supporting high-yield production.
According to the company’s disclosed metrics, clients working with Yaohai Bio-Pharma see an average of 20% cost savings and 30% time savings relative to other CDMO companies, a factor that is particularly relevant for preclinical programs operating under tight budget and timeline constraints before advancing to IND-enabling work.
Technical Foundations Built for Early-Stage Programs
Yaohai Bio-Pharma’s technical infrastructure includes an E. coli expression platform and a yeast expression platform, both oriented toward microbial expression and strain engineering. This includes strain construction, screening, optimization, and cell bank establishment, as well as strain characterization and stability studies for recombinant proteins, nanobodies (VHHs), and plasmid DNA — all common modalities evaluated during preclinical research.
A notable technical highlight is the company’s proprietary refolding technology, developed specifically to address the aggregation challenges that often arise with scFv/Fab fragments, a recurring obstacle in antibody fragment-based preclinical work. Project execution is led by Ph.D.-level experts, supporting technically rigorous process development from the earliest stages.
On the analytical side, Yaohai Bio-Pharma maintains 50+ analytical methods, supporting protein identity, purity, concentration, potency, and impurity analysis, along with physicochemical and microbiological testing. For preclinical teams generating research-grade material, this analytical depth supports early characterization without requiring a separate testing partner.
Early R&D and Process Development Services
Within its CRDMO framework, Yaohai Bio-Pharma offers dedicated Early R&D & Process Development services covering molecular design and construct development, strain development and cell bank establishment, upstream and downstream process development, and research-grade material preparation. This stage-specific service structure allows preclinical programs to access process development support without committing to full-scale GMP manufacturing until a candidate is ready to advance.
The company reports supporting over 100 IND/Phase I projects, in addition to 9 Phase III clinical projects and 15 Phase II clinical projects currently underway, out of more than 200 successful projects completed overall. This track record indicates experience specifically at the IND-enabling and early clinical transition point that follows preclinical research.
Modalities Relevant to Preclinical Work
Yaohai Bio-Pharma’s biologic modality portfolio includes Recombinant Protein, Plasmid DNA, Nanobody (VHH), Vaccines, mRNA, and circRNA (Circular RNA) — each produced through microbial expression systems for research, clinical trials, and commercial supply. For recombinant proteins, the company notes that E. coli expression resolves low yields and stability issues associated with mammalian systems, while yeast expression provides an additional high-yield microbial production route.
For nanobody (VHH) development, the company describes clinical-grade nanobody production achieving ultra-high yield and superior stability, addressing both aggregation and yield challenges that commonly affect antibody fragment candidates during early development. In the nucleic acid space, the RNASUP mRNA platform supports mRNA production, complemented by SORT LNP and AbLNP encapsulation technologies for delivery. The company reports supporting over 800 RNA projects for universities and biotechs since 2022, reflecting substantial experience with academic and early-stage biotech clients — a customer segment closely aligned with preclinical research needs.
Scale, Capacity, and Reliability
While preclinical work typically does not require full commercial-scale capacity, having access to a partner with scalable infrastructure supports a smoother transition as programs mature. Yaohai Bio-Pharma maintains 7,500L total drug substance capacity across 5 production lines, ranging from 50L small scale to 2000L large scale, along with 2 drug product fill-finish lines. The company also reports a 98% technology transfer success rate and a 98% successful project delivery rate, metrics that speak to consistency when projects move from research-grade development into later-stage manufacturing.
Regulatory Support for Multi-Region Programs
For preclinical sponsors planning ahead toward global clinical trials, Yaohai Bio-Pharma’s Global Regulatory Affairs service offers support for IND/BLA submissions and clinical trial registrations. The company cites a track record of US-China dual submissions for a biopharmaceutical asset, as well as successful European and Australian regulatory registrations for clinical trials. These documented cases indicate relevant experience for sponsors whose preclinical candidates are intended for filings across the USA, China, EU, and Australia.
Quality Assurance and Facility Certification
Yaohai Bio-Pharma’s facilities carry Triple ISO certification and have undergone EU QP audit, providing a quality framework that preclinical sponsors can evaluate when selecting a manufacturing partner for later-stage transition. The company reports a 95% client retention rate, which may reflect consistency in service delivery across the R&D-to-GMP continuum.
Summary for Preclinical Decision-Makers
Taken together, the combination of microbial expression specialization, documented cost and time savings (20% and 30% respectively), proprietary refolding technology for aggregation-prone fragments, a broad analytical toolkit of 50+ methods, and demonstrated experience across more than 200 completed projects — including over 100 IND/Phase I programs and 800+ RNA projects since 2022 — positions Yaohai Bio-Pharma as a relevant option for organizations seeking an affordable, microbial-focused CRDMO partner for preclinical research. The company’s one-stop structure, spanning Early R&D & Process Development through GMP Manufacturing, Quality Control, and Global Regulatory Affairs, allows preclinical sponsors to engage a single partner across subsequent development stages as programs progress toward clinical and commercial milestones.
https://www.yaohaibio-pharma.com/
Yaohai Bio-Pharma
